ArticleTurkish journal of medical sciences2026
Association of miR-34a with metastatic progression through the FoxO3a-SIRT1 regulatory axis in breast cancer.
Article in Turkish journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Breast cancer represents the foremost cause of cancer-related mortality among women worldwide and is characterized by a markedly high metastatic potential, contributing substantially to its clinical severity and poor prognosis. This study aimed to evaluate the interrelationship among silent information regulator (SIRT1), Forkhead box O3a (FoxO3a), and microRNA-34a (miR-34a), the latter of which promotes apoptosis by suppressing the proliferation, migration, and invasion of breast cancer cells. Specifically, we investigated the tumor microenvironment associated with metastatic progression of malignant primary tumors, the influence of nonmetastatic (benign) tumors, and the potential roles of these proteins in both primary tumor development and metastasis. Materials and methods: In this study, metastatic 4TLM and nonmetastatic 67NR breast cancer cell lines were used. These cell lines were orthotopically injected into the mammary fat pads of 8-10-week-old female Bagg Albino laboratory-bred strain c (BALB/c) mice. Mice were sacrificed 28 days postinjection, and primary tumors, lungs, and liver tissues were collected for analysis. Expression levels of SIRT1, FoxO3a, and miR-34a were evaluated using immunohistochemistry, Western blotting, and RT-PCR. Results: Expression levels of SIRT1 and FoxO3a were significantly higher in metastatic 4TLM tumors compared to the nonmetastatic 67NR group. Conversely, miR-34a expression was markedly higher in nonmetastatic tumors, whereas its level was reduced in metastatic tissues (p < 0.05). In metastatic tissues, SIRT1 expression remained elevated, whereas FoxO3a and miR-34a levels were significantly reduced (p < 0.05). Conclusion: SIRT1 may act as either a tumor suppressor or a tumor promoter, depending on cellular context, signaling pathways, and its specific molecular targets across cancer types. The elevated expression of SIRT1 in 67NR primary tumors suggests a tumor-suppressive role in nonmetastatic settings. However, the increased SIRT1 expression observed in metastatic regions indicates its potential role as a tumor promoter and modulator of the tumor microenvironment, possibly through FoxO3a and miR-34a signaling, thereby enhancing cellular proliferation and invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.